Company's Partner Completes Trial Production of a New Antiviral Medicine
Monday , October 15, 2007 08:21ET
HANGZHOU, China, Oct. 15 /PRNewswire-FirstCall/ -- China Biopharma, Inc. (OTC Bulletin Board: CBPC) announced today that its partner, Soonfast Pharmaceutical Science & Technology Co., Ltd. ("Soonfast") has successfully completed its trial production of a new antiviral product. This all-natural medicine has been approved in China for external use to treat human papillomavirus ("HPV") and herpes simplex virus ("HSV"). Tests have shown an inhibitory effect on the growth of HPV and HSV, and the medicine can reduce the infection from HPV and HSV up to 90% only in 2-3 days. Experiments have also proved that the herbal can kill all of the HPV types 6/11/16/18 and 33. The sample product is available for distributors now and the commercial product will be available next month.
HPV infection is common across all races and socio-economic groups and is prevalent throughout the world in sexually active persons. HPVs are the most common sexually transmitted viral agents in the United States, infecting up to 20% of people aged 15 to 49. In the last 30 years, the incidence of HPV infection has increased dramatically. Despite the prevalence of HPV, no available drug therapy effectively eliminates HPV infection and replication or prevents HPV-associated malignant progression.
According to the agreement reached with Soonfast in June this year, China Biopharma has the right to distribute this new all-natural antiviral medicine in overseas market. The successful trial production has now quickened some approval process for China Biopharma to launch commercial sales on overseas market including Europe and the United States. The company and Soonfast also plan to jointly conduct studies on its extracts in both China and USA so as to obtain approval necessary for selling this medicine as an over-the-counter drug. The company believes this new medicine would bring in significant revenue and profit in the near future once it is successfully introduced into the market.
About China Biopharma, Inc.
China Biopharma Inc. is a fast-growing biopharmaceutical company based in China. Through its operating subsidiaries, the company develops and distributes biopharmaceutical and pharmaceutical products throughout the world's most populated country, China. Products include human vaccines and other pharmaceutical drugs. Leveraging its investment and ownership of local Chinese bio-pharmaceutical companies, and partnerships with international biopharmaceutical companies, China Biopharma is building a highly-competitive platform for growth in China as well as new world markets, including the U.S. and Europe. For more information, visit its website at http://www.chinabiopharma.net.
Safe Harbor Statement
Some of the statements here discuss future events and developments, including the Company's future business strategy and its ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements can generally be identified by words such as "expect," "anticipate," "believe," "estimate," "intend," "plan," and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company's operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company's new and uncertain business model, uncertainty regarding acceptance of the Company's products and services and the Company's limited operating history.
posted
Another nice gainer from O T C R E P O R T E R . C O M !! Their TKAT " Morning ALERT " up again today over 40%. Up 220% since their initial alert on 10/4. Nice gains .... imho
-------------------- " Cash is King "
IP: Logged |
Company's Partner Completes Trial Production of A New Antiviral Medicine
2007-10-15
Hangzhou, China, October 15, 2007 – China Biopharma, Inc. (OTCBB: CBPC) announced today that its partner, Soonfast Pharmaceutical Science & Technology Co., Ltd. ("Soonfast") has successfully completed its trial production of a new antiviral product. This all-natural medicine has been approved in China for external use to treat human papillomavirus ("HPV") and herpes simplex virus ("HSV"). Tests have shown an inhibitory effect on the growth of HPV and HSV, and the medicine can reduce the infection from HPV and HSV up to 90% only in 2-3 days. Experiments have also proved that the herbal can kill all of the HPV types 6/11/16/18 and 33. The sample product is available for distributors now and the commercial product will be available next month.
IP: Logged |
Influenza (Flu) - The Chinese Centers for Disease Control & Prevention (CDCs) recommends immunizing against influenza as soon as the vaccine becomes available. China Biopharma’s flu vaccine, approved by the Chinese State Food and Drug Administration (SFDA) for distribution, is among the first to be delivered and made available to the general public in China for the 2006-2007 Flu Season. Through its manufacturing joint venture partner, Zhejiang Tianyuan Biopharma Co., the Company began shipping its first batch of flu vaccines to local CDCs, the Xi’an Social Security Pension Fund Program, insurance companies and hospitals in August 2006. Management expects to deliver a total of three million doses by year’s end.
Epidemic Hemorrhagic Fever (EHF) – EHF is carried by rodents in Asia and causes devastating lung infections in humans. CBPC owns over 90% market share in China against this disease, and estimates it will sell one million doses of its EHF vaccine in 2006.
Epidemic Japanese Encephalitis (EJE) – EJE, the "Plague of the Orient," is the leading cause of viral encephalitis in Asia. An inflammation of the brain, EJE exists in epidemic proportions in temperate and northern tropical regions. Rates of EJE are steady and even increasing in the areas of South and Southeast Asia. (source: Public Health Agency of Canada). China Biopharma’s EJE vaccine was approved by the SFDA in December 2005 and will be available in China in early 2007.
Developing Products
Group A ,C, Y, W135 Meningococcal Polysaccharide – CPBC has successfully completed Phase III clinical trials and pending SFDA approval, the vaccine will be commercialized in early 2008.
Avian (“Bird Flu”) H5N1 Virus – By February 2004, the avian or “bird” flu spread across 10 countries in Asia and caused dozens of deaths in Thailand and Vietnam. In China, the bird flu affected more than half of all provinces and territories. CBPC stands to be a major player in creating and mass-producing a vaccine for a potential pandemic bird flu outbreak. In June 2006, China Biopharma received a copy of the H5N1 virus (a deadly virus transmitted from bird to human), and has begun animal testing on a vaccine.
Allergy vaccine – According to the American Academy of Allergy, Asthma and Immunology, 1 in 4 people suffer from an allergy worldwide. In fact, the allergy treatment and relief medicine category is growing over 10% per annum and is estimated to be an $18 billion global market. China Biopharma is developing an allergy vaccine in strategic alliance with a European allergy vaccine producer (who markets a similar vaccine in Europe) to reach the Chinese allergy market. China Biopharma will perform clinical studies, apply for SFDA registration, and retain the exclusive copyrights to market the vaccine throughout China. http://www.chinabiopharma.com.cn/index_4_1.asp
China Biopharma, Inc. (stock symbol CBPC.OB), is a fast growing provider of human vaccine products in China. Through its wholly owned subsidiary, China Biopharma Limited, the Company owns the majority interest of Zhejiang Tianyuan Biotech Co., Ltd. The Company's current products consist of human vaccines against influenza (flu), epidemic hemorrhagic fever (HF), and Japanese encephalitis (JE). With its investment and ownership of local Chinese biopharmaceutical companies, the Company plans to build a leading biopharmaceutical company in China by leveraging its manufacturing and marketing capabilities and introducing advanced technologies, best products, and experienced management teams.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
